Skip to main content
OpenTrials
Completed

NCT Number: NCT03679767

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metastatic Non-small Cell Lung Cancer Adenocarcinoma Bronchial Neoplasms Carcinoma Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Clear-cell metastatic renal cell carcinoma Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Locally Advanced Renal Cell Carcinoma Locally Advanced Urothelial Cancer Lung Diseases Lung Neoplasms Male Urogenital Diseases Melanoma Metastatic Clear-Cell Renal Cell Carcinoma Metastatic Melanoma Metastatic Urothelial Cancer Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Respiratory Tract Diseases Respiratory Tract Neoplasms Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases Thoracic Neoplasms Unresectable Melanoma Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

LKH Graz, Graz, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed diagnosis of one of the following: treatment-naïve metastatic non-small cell lung cancer with high PD-L1 expression (tumor proportion score ≥ 50%) and no epidermal growth factor receptor (EGFR), alkaline phosphatase (ALK), or ROS activating genomic tumor aberrations; locally advanced or metastatic urothelial carcinoma in participants who are not eligible for cisplatin therapy and whose tumors express PD-L1 with a combined positive score ≥ 10; unresectable or metastatic melanoma; locally advanced or metastatic renal cell carcinoma with clear cell component (with or without sarcomatoid features) and having received no prior systemic therapy.
  • Measurable disease per RECIST v1.1.
  • Eastern Cooperative Oncology Group performance status 0 to 1.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

  • Receipt of anticancer therapy or participation in another interventional clinical study within 21 days before the first administration of study drug.
  • Prior treatment with PD-1 or PD-L1 directed therapy (other immunotherapies may be acceptable with prior approval from the medical monitor).
  • Radiotherapy within 14 days of first dose of study treatment with the following caveats: 28 days for pelvic radiotherapy; 6 months for thoracic region radiotherapy that is > 30 Gy.
  • Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of anemia not requiring transfusion support and any grade of alopecia). Endocrinopathy, if well-managed, is not exclusionary and should be discussed with sponsor medical monitor.
  • Has not recovered adequately from toxicities and/or complications from surgical intervention before starting study drug.
  • Laboratory values outside the protocol-defined range at screening.
  • Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 3 years of study entry.
  • Active autoimmune disease requiring systemic immunosuppression in excess of physiologic maintenance doses of corticosteroids (> 10 mg of prednisone or equivalent).
  • Evidence of interstitial lung disease or active noninfectious pneumonitis.
  • Known active central nervous system metastases and/or carcinomatous meningitis.
  • Known active hepatitis B antigen, hepatitis B virus, or hepatitis C virus infection.
  • Active infections requiring systemic therapy.
  • Known to be HIV-positive, unless all of the following criteria are met: CD4+ count ≥ 300/μL, undetectable viral load, receiving antiretroviral therapy.
  • Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).
  • Impaired cardiac function or clinically significant cardiac disease.
  • Is pregnant or breastfeeding.
  • Has received a live vaccine within 28 days of the planned start of study drug.

Treatment and study plan

Retifanlimab

Drug

Retifanlimab administered intravenously at 500 mg every 4 weeks

Other names: INCMGA00012

Primary outcomes

  1. Overall Response Rate (ORR)

    Time frame: up to 25.9 months

    ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1), as determined by the investigator, at any post-Baseline visit until new anti-cancer therapy or first Progressive Disease. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

Secondary outcomes

  1. Duration of Response (DOR)

    Time frame: up to 24.0 months

    DOR was defined as the time from initial objective response (CR or PR) per RECIST v1.1 until the first observation of documented disease progression (PD), as determined by the investigator, or death due to any cause. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.

  2. Disease Control Rate (DCR)

    Time frame: up to 25.9 months

    DCR was defined as the proportion of participants with an overall response of CR, PR, or stable disease (SD), per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.

  3. Progression-free Survival (PFS)

    Time frame: up to 25.9 months

    According to RECIST 1.1, PFS was defined as the length of time from the initial infusion of study drug until the earliest date of disease progression, determined by investigator assessment, or death due to any cause, if occurring sooner than progression.

  4. Overall Survival

    Time frame: up to 28.2 months

    Overall survival was defined as the time in months between the first dose date (Day 1) and the date of death due to any cause.

  5. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: up to approximately 2.3 years

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of retifanlimab and until the earlier of 90 days of the last administration of retifanlimab and new anti-cancer therapy start if any, are reported.

  6. First-dose Cmax of Retifanlimab

    Time frame: preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycle 1

    Cmax was defined as the maximum observed plasma or serum concentration of retifanlimab.

  7. Cmax of Retifanlimab at Steady-state

    Time frame: preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycles 1, 2, 4, and 6 (up to approximately 168 days; each cycle was 28 days)

    Cmax was defined as the maximum observed plasma or serum concentration of retifanlimab.

  8. First-dose Tmax of Retifanlimab

    Time frame: preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycle 1

    tmax was defined as the time to the maximum concentration of retifanlimab.

  9. Tmax of Retifanlimab at Steady-state

    Time frame: preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycles 1, 2, 4, and 6 (up to approximately 168 days; each cycle was 28 days)

    tmax was defined as the time to the maximum concentration of retifanlimab.

  10. First-dose Cmin of Retifanlimab

    Time frame: preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycle 1

    Cmin was defined as the minimum observed plasma or serum concentration over the dose interval of retifanlimab.

  11. Cmin of Retifanlimabv at Steady-state

    Time frame: preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycles 1, 2, 4, and 6 (up to approximately 168 days; each cycle was 28 days)

    Cmin was defined as the minimum observed plasma or serum concentration over the dose interval of retifanlimab.

  12. First-dose AUC0-t of Retifanlimab

    Time frame: preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycle 1

    AUC0-t was defined as the area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t of retifanlimab.

  13. AUC0-t of Retifanlimab at Steady-state

    Time frame: preinfusion and 10 minutes postinfusion (± 10 minutes) on Day 1 of Cycles 1, 2, 4, and 6 (up to approximately 168 days; each cycle was 28 days)

    AUC0-t was defined as the area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t of retifanlimab.

Sponsors and collaborators

Lead sponsor

Incyte Corporation

Industry

Registry information

Official study title

A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

Important dates

Study start
2019
Primary completion
2021
Study completion
2022
First posted
Sep 20, 2018
Registry last updated
Jul 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.